Skip to main content
SpringerLink
Log in

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 26 April 2014

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Henry D , Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2013 Oct 26. [Epub ahead of print]

  2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. doi:10.1200/JCO.2010.29.7101, Epub 2010

    Article  CAS  PubMed  Google Scholar 

  3. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132

    Article  CAS  PubMed  Google Scholar 

  5. Saad F, Brown JE, Poznak CV et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347

    Article  CAS  PubMed  Google Scholar 

  6. Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092

    Article  CAS  PubMed  Google Scholar 

  7. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M (2012) Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78:c85

    PubMed  Google Scholar 

  8. Lescaille G, Coudert AE, Baaroun V, Ostertag A, Charpentier E, Javelot MJ, Tolédo R, Goudot P, Azérad J, Ariane Berdal A, Jean-Philippe Spano JP, Ruhin B, Descroix V (2014) Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone 58:103–107

    Article  CAS  PubMed  Google Scholar 

  9. Bozas G, Allgar V, Greenwood G, Maraveyas A, Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid. (2011) ASCO Annual Meeting Abstract. J Clin Oncol 29: 2011 (suppl; abstr e15116)

  10. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P (2012) Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 107(10):1665–1671. doi:10.1038/bjc.2012.385

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Hansen PJ, Knitschke M, Draenert FG, Irle S, Neff A (2013) Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment—a grossly underestimated risk? Clin Oral Investig 17:1829–1837. doi:10.1007/s00784-012-0873-3

    Article  PubMed  Google Scholar 

  12. Fusco V, Porta C, Bedogni A, Saia G, Scoletta M, Bonacina R, Vescovi P, LoRe S, Campisi G (2013) Osteonecrosis of the jaw (ONJ) in patients with renal cell cancer (RCC) treated with bisphosphonates and sunitinib or other biological agents: characteristics of 39 cases in a multicenter survey. ECCO European Cancer Congress 2013 abstract. Eur J Cancer 49(suppl2):abs 1391

    Google Scholar 

Download references

Disclosure/conflict of interest

None.

Author information

Authors and Affiliations

  1. Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Via Venezia 16, 15121, Alessandria, Italy

    Vittorio Fusco

  2. Department of Surgery, Section of Oral and Maxillofacial Surgery, University and Hospital Trust of Verona, P.le L.A. Scuro 10, Verona, 37134, Italy

    Alberto Bedogni

  3. Department of Surgical, Oncological and Oral Sciences- Sector of Oral Medicine, Palermo University, Via del Vepro 129, Palermo, 90127, Italy

    Giuseppina Campisi

Authors
  1. Vittorio Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Bedogni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppina Campisi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vittorio Fusco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fusco, V., Bedogni, A. & Campisi, G. Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. Support Care Cancer 22, 1737–1738 (2014). https://doi.org/10.1007/s00520-014-2159-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2159-6

Keywords

Search

Navigation